Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00445042 · ClinicalTrials.gov registry record · Phase 2

Safety and Toxicity Study of Sorafenib in Patients With Kidney Cancer

A Phase 2 study of Carcinoma, Renal Cell, sponsored by The Methodist Hospital Research Institute.

Completed
Registry status
Phase 2
Development phase
71
Enrollment target
1
Study location

NCT00445042 is a Phase 2 study of Carcinoma, Renal Cell that has completed, run by The Methodist Hospital Research Institute. The registered enrollment target is 71 participants, below the 281-participant average among 34 other Carcinoma, Renal Cell trials with a reported enrollment target (75% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00445042, a Phase 2 study of Carcinoma, Renal Cell, has completed, sponsored by The Methodist Hospital Research Institute.

COMPLETED
Registry status
Phase 2
Development phase
71 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to determine the safety and toxicity levels of Dose Escalated Sorafenib in the treatment of patients with renal cancer.

Conditions Studied

Carcinoma, Renal Cell

Interventions

  • DRUG Sorafenib

Study Locations (1)

Texas

  • Methodist Hospital - Baylor College of Medicine - Houston

Trial Details

FieldValue
Enrollment Target 71 participants
Start Date 2005-11
Est. Completion 2008-10
Phase Phase 2

Sponsor

The Methodist Hospital Research Institute

126 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00445042

The ClinicalTrials.gov registry entry for NCT00445042 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 71 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 281-participant average among 34 other Carcinoma, Renal Cell trials with a reported enrollment target (75% lower). The listed sponsor is The Methodist Hospital Research Institute, which has 126 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Carcinoma, Renal Cell appearing as the primary indexed condition, and to 1 intervention - of which Sorafenib is the first listed.

NCT00445042 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT00445042 about?

NCT00445042 is a clinical study titled "Safety and Toxicity Study of Sorafenib in Patients With Kidney Cancer". The purpose of this study is to determine the safety and toxicity levels of Dose Escalated Sorafenib in the treatment of patients with renal cancer.

What is the current status of trial NCT00445042?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 71 participants. The study started on 2005-11. Estimated completion is 2008-10.

What conditions does trial NCT00445042 study?

This clinical trial studies the following conditions: Carcinoma, Renal Cell.

What interventions are being tested in trial NCT00445042?

The interventions under investigation include: Sorafenib (DRUG).

Who is sponsoring clinical trial NCT00445042?

This trial is sponsored by The Methodist Hospital Research Institute, which has 126 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00445042 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Carcinoma, Renal Cell

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Carcinoma, Renal Cell

All registered trials for this condition

Texas

All trials with a study site in Texas

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.